4-(Trifluoromethylthio)bromobenzene

We are 4-(Trifluoromethylthio)bromobenzene CAS:333-47-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-(Trifluoromethylthio)bromobenzene
CAS.NO:333-47-1
Synonyms:4-(Trifluoromethylthio)bromobenzene
1-bromo-4-(trifluoromethylsulfanyl)benzene
1-Bromo-4-[(trifluoromethyl)sulfanyl]benzene
4-Bromophenyl trifluoromethyl sulphide
4-trifluoromethylthio-1-bromobenzene
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 164.9±40.0 °C at 760 mmHg
Molecular Formula C7H4BrF3S
Molecular Weight 257.071
Flash Point 53.5±27.3 °C
Vapour Pressure 2.5±0.3 mmHg at 25°C
Index of Refraction 1.547
 
Specification:
Appearance:Colorless to light yellow transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.

4-(Trifluoromethylthio)bromobenzene


Related News: Social media users — including numerous medical experts — questioned whether the findings were supported by clinical evidence from treating coronavirus patients.1,3-Dibromobenzene CAS:108-36-1 In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.BROMOIODOMETHANE From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.4-bromo-2-fluoro-1-methoxybenzene Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.

Related Products
Product Name
1-Bromo-8-fluorooctane View Details
Pyridine-3-Sulfonyl Chloride View Details
Cyclopropylboronic acid View Details
5-Bromo-2-chloro-4-methylpyridine manufacturer chloromethyl(trimethyl)silane manufacturer 4-Methyl-5-vinylthiazole manufacturer (2S)-trans-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid manufacturer N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide manufacturer